文献速递血栓与止血

T细胞与髓源性抑制细胞在难治性免疫性血小板减少症中的作用

The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2023-01-01

本文综述了免疫性血小板减少症(ITP)中T细胞和髓源性抑制细胞(MDSC)的作用,讨论了各种治疗如何影响这两个细胞群,并聚焦于探索特定治疗难治机制和遗传基础的研究,强调预测治疗反应仍存挑战。

要点

  • ITP发病机制涉及针对血小板的免疫失调,异常T细胞 compartment 已确立作用。
  • 治疗使血小板升高的ITP患者T细胞谱有所改善,而难治患者似保留原有T细胞异常。
  • MDSC正成为ITP免疫病理和治疗反应的关键贡献者。

核心结论

  • ITP以针对血小板的免疫失调为特征,影响血小板破坏和生成;异常T细胞在ITP发病中已确立作用,MDSC也正成为关键贡献者。

研究设计与样本

  • 综述,聚焦于探讨特定治疗难治的潜在机制和/或遗传基础的研究。

主要发现

  • 治疗使ITP患者血小板升高时T细胞谱改善,而难治患者似保留原有T细胞异常。
  • MDSC正成为ITP免疫病理和治疗反应的关键贡献者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出识别预测治疗反应的因素和机制仍存挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is characterized by a dysregulated immune response against platelets, affecting both their destruction and production. A role for an abnormal T-cell compartment has been established in ITP pathogenesis and treatments that increase platelet counts in patients with ITP have shown improvements in T-cell profiles. On the other hand, patients who were refractory to treatment appear to retain the T-cell abnormalities as before. Myeloid-derived suppressive cells (MDSCs) are also emerging as key contributors to the immune pathology of ITP and response to treatment. In this review, we will discuss how various treatments affect the T-cell and MDSC compartments in ITP. The review will focus on studies that have examined the underlying mechanisms and/or genetic basis responsible for refractoriness to a given treatment and highlight remaining challenges in identifying factors and mechanisms to predict response to treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yazdanbakhsh K, Provan D, Semple JW, et al. The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia. Br J Haematol. 2023. PMID: 37735552. doi:10.1111/bjh.19079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。